|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.97 USD | -5.22% |
|
-8.12% | -13.03% |
| 23/01 | Ocular Therapeutix Finance Chief Donald Notman Takes Medical Leave; Interim CFO Named | MT |
| 23/01 | Ocular Therapeutix, Inc. Announces Chief Financial Officer Changes, Effective January 20, 2026 | CI |
| Capitalization | 1.49TCr 1.27TCr 1.18TCr 1.1TCr 2.05TCr 1,37100Cr 2.17TCr 13TCr 5.34TCr 65TCr 5.59TCr 5.48TCr 2,35400Cr | P/E ratio 2025 * |
-159x | P/E ratio 2026 * | 47.5x |
|---|---|---|---|---|---|
| Enterprise value | 1.53TCr 1.31TCr 1.21TCr 1.13TCr 2.11TCr 1,41000Cr 2.23TCr 14TCr 5.49TCr 67TCr 5.75TCr 5.64TCr 2,42200Cr | EV / Sales 2025 * |
2.55x | EV / Sales 2026 * | 2.03x |
| Free-Float |
52.89% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: DraftKings Inc.
| 1 day | -5.22% | ||
| 1 week | -8.12% | ||
| Current month | -13.03% | ||
| 1 month | -13.03% | ||
| 3 months | -9.18% | ||
| 6 months | -31.95% | ||
| Current year | -13.03% |
| 1 week | 29.85 |  | 33.28 |
| 1 month | 29.85 | | 36.98 |
| Current year | 29.85 | | 36.98 |
| 1 year | 26.23 | | 53.61 |
| 3 years | 14.01 | | 53.61 |
| 5 years | 9.77 | | 74.38 |
| 10 years | 0 | | 74.38 |
| Manager | Title | Age | Since |
|---|---|---|---|
Paul Liberman
COO | Chief Operating Officer | 42 | 01/01/2015 |
Matthew Kalish
PRN | Corporate Officer/Principal | 44 | 31/12/2011 |
Jason Robins
CEO | Chief Executive Officer | 45 | 31/12/2011 |
| Director | Title | Age | Since |
|---|---|---|---|
Jason Robins
CHM | Chairman | 45 | 01/04/2020 |
Matthew Kalish
BRD | Director/Board Member | 44 | 01/04/2020 |
Paul Liberman
BRD | Director/Board Member | 42 | 01/04/2020 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.22% | -8.12% | -27.50% | +100.87% | 1.49TCr | |
| -3.47% | -7.19% | -34.56% | +7.31% | 3.06TCr | |
| -0.47% | -0.50% | -16.66% | +68.50% | 2.42TCr | |
| +1.36% | +3.62% | +31.65% | -23.86% | 2.35TCr | |
| +0.54% | +0.91% | +3.99% | -37.47% | 1.95TCr | |
| +0.07% | -1.70% | -30.46% | -49.97% | 1.31TCr | |
| -0.39% | -1.56% | +2.64% | +6.54% | 771.89Cr | |
| -1.01% | -0.95% | +7.60% | +32.58% | 746.3Cr | |
| -0.33% | -4.06% | -17.98% | -16.67% | 715Cr | |
| Average | -0.99% | -2.20% | -9.03% | +9.76% | 1.65TCr | |
| Weighted average by Cap. | -1.12% | -2.18% | -10.14% | +10.95% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 601.49Cr 511.56Cr 474.17Cr 443.1Cr 826.03Cr 55TCr 875.52Cr 5.42TCr 2.15TCr 26TCr 2.26TCr 2.21TCr 95TCr | 732.57Cr 623.05Cr 577.5Cr 539.67Cr 1.01TCr 67TCr 1.07TCr 6.6TCr 2.62TCr 32TCr 2.75TCr 2.69TCr 1,15600Cr |
| Net income | -9.3Cr -7.91Cr -7.33Cr -6.85Cr -13Cr -854.09Cr -14Cr -84Cr -33Cr -403.26Cr -35Cr -34Cr -1.47TCr | 32Cr 27Cr 25Cr 24Cr 44Cr 2.93TCr 46Cr 287.65Cr 114.2Cr 1.38TCr 119.72Cr 117.27Cr 5.04TCr |
| Net Debt | 43Cr 36Cr 34Cr 32Cr 59Cr 3.93TCr 62Cr 385.46Cr 153.03Cr 1.86TCr 160.43Cr 157.15Cr 6.75TCr | -7.94Cr -6.75Cr -6.26Cr -5.85Cr -11Cr -729.43Cr -12Cr -72Cr -28Cr -344.4Cr -30Cr -29Cr -1.25TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | 29.97 $ | -5.22% | 1,71,40,558 |
| 22/26/22 | 31.62 $ | +0.13% | 1,79,73,203 |
| 21/26/21 | 31.58 $ | -2.08% | 1,14,83,733 |
| 20/26/20 | 32.25 $ | -1.13% | 1,74,99,204 |
| 16/26/16 | 32.62 $ | -8.01% | 2,80,29,942 |
Delayed Quote Nasdaq, January 24, 2026 at 02:30 am IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- DKNG Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition